La Jolla Pharmaceutical Company (NASDAQ: LJPC) is focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The company has several product candidates in development, including LJPC-501, the company’s proprietary formulation of angiotensin II, a naturally-occurring regulator of blood pressure, and LJPC-401, its novel formulation of hepcidin, an endogenous peptide hormone that controls and regulates iron metabolism. For more information, visit the company’s website at www.lajollapharmaceutical.com.